Results 51 to 60 of about 8,510 (199)

Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future [PDF]

, 2017
Intratumor heterogeneity, which fosters tumor evolution, is a key challenge in cancer medicine. Here, we review data and technologies that have revealed intra-tumor heterogeneity across cancer types and the dynamics, constraints, and contingencies ...
McGranahan, N, Swanton, C
core   +1 more source

In-depth Analysis of Lorlatinib-related neurocognitive Adverse Events in Patients With Non–small-cell Lung Cancer [PDF]

, 2023
Introduction: Lorlatinib is a potent, brain penetrant, next-generation ALK/ROS1 TKI, with high response rates and durable responses, including the brain.
Brandts, Lloyd, Broen, Martijn, Dijkstra, Jeanet, Dingemans, Anne Marie, Hendriks, Lizza, Paats, Marthe, Schoenmaekers, Janna, van der Wekken, Anthonie   +7 more
core   +5 more sources

Efficacy of lorlatinib in lung carcinomas carrying distinct ALK translocation variants: The results of a single-center study

Translational Oncology, 2021
Background: Lorlatinib is a novel potent ALK inhibitor, with only a few studies reporting the results of its clinical use. Methods: This study describes the outcomes of lorlatinib treatment for 35 non-small cell lung cancer patients with ALK ...
Sergey V. Orlov, Aglaya G. Iyevleva, Elena A. Filippova, Alexandra M. Lozhkina, Svetlana V. Odintsova, Tatiana N. Sokolova, Natalia V. Mitiushkina, Vladislav I. Tiurin, Elena V. Preobrazhenskaya, Alexandr A. Romanko, Alexandr S. Martianov, Alexandr O. Ivantsov, Svetlana N. Aleksakhina, Alexandr V. Togo, Evgeny N. Imyanitov   +14 more
doaj   +1 more source

Detection of ALK fusion transcripts in FFPE lung cancer samples by NanoString technology [PDF]

, 2017
Background: ALK-rearranged lung cancers exhibit specific pathologic and clinical features and are responsive to anti-ALK therapies. Therefore, the detection of ALK-rearrangement is fundamental for personalized lung cancer therapy. Recently, new molecular
A Cesano, Adriana Cruvinel Carloni, Adriane F. Evangelista, AP Becker, AS Crystal, AT Shaw, Cristovam Scapulatempo-Neto, DR Camidge, DW-S Wong, EL Kwak, EM Gaughan, FH Wilson, Flávia E. de Paula, I Dagogo-Jack, Iberê Cauduro Soares, J Wu, JM Heuckmann, Jose Elias Miziara, JS Reis-Filho, K McKeage, K Rikova, K Takeuchi, LS Yamane, M Soda, Maicon F. Zanon, Maressa Ferreira-Neto, Mariana Andozia Morini, ME Lira, MM Kulkarni, MW Wynes, Pedro de Marchi, R Roskoski, Rui M. Reis, S-H Jung, SM Ali, SW Morris, T-M Rogers, YP Mossé   +37 more
core   +2 more sources

Lorlatinib Tolerability and Association With Clinical Outcomes in Patients With Advanced ALK- or ROS1-Rearranged NSCLC: A Brief Report

JTO Clinical and Research Reports, 2023
Introduction: Treatment with lorlatinib for patients with advanced ALK- and ROS1-rearranged NSCLC (ALK+ and ROS1+ NSCLC) is associated with a unique set of adverse events (AEs) often requiring dose reduction.
Rohit Thummalapalli, MD, Noura J. Choudhury, MD, Fiona Ehrich, MS, Tyler Beardslee, PharmD, Danielle Brazel, MD, Shannon S. Zhang, MD, Shelby Merchant, PharmD, Monica F. Chen, MD, Glenn Heller, PhD, Suresh S. Ramalingam, MD, Sai-Hong Ignatius Ou, MD, PhD, Kathryn F. Mileham, MD, Gregory J. Riely, MD, PhD   +12 more
doaj   +1 more source

Chronic myeloid leukemia cells require the bone morphogenic protein pathway for cell cycle progression and self-renewal [PDF]

, 2018
Leukaemic stem cell (LSC) persistence remains a major obstacle to curing chronic myeloid leukaemia (CML). The bone morphogenic protein (BMP) pathway is deregulated in CML, with altered expression and response to the BMP ligands shown to impact on LSC ...
Busch, Caroline, Copland, Mhairi, Jørgensen, Heather, Morrison, Heather, O'Brien, Stephen, Toofan, Parto, Wheadon, Helen   +6 more
core   +2 more sources

Patient-reported outcomes from the randomized phase 3 CROWN study of first-line lorlatinib versus crizotinib in advanced ALK-positive non-small cell lung cancer [PDF]

, 2022
Crizotinib; Lorlatinib; Patient-reported outcomesCrizotinib; Lorlatinib; Resultados informados por el pacienteCrizotinib; Lorlatinib; Resultats informats pel pacientObjectives Quality of life (QoL) for patients with non-small cell lung cancer (NSCLC) is
Bauer, Todd, de Marinis, Filippo, Felip Font, Enriqueta, Iadeluca, Laura, Mazieres, Julien, Shaw, Alice Tsang, Solomon, Benjamin   +6 more
core   +1 more source

Concordance between circulating tumor cells and clinical status during follow-up in anaplastic lymphoma kinase (ALK) non-small-cell lung cancer patients [PDF]

, 2017
Background: The identification of anaplastic lymphoma kinase (ALK) rearrangements is found in approximately 5% of non-small-cell lung cancers (NSCLCs).
Calvo, Virginia, Coronado, María José, Cruz-Bermúdez, Alberto, Cruz-Bermúdez, Juan Luis, Franco, Fernando, García-Grande, Aránzazu, Gutiérrez, Lourdes, Martín Ruiz-Valdepeñas, Asunción, Martín, Paloma, Provencio, Mariano, Pérez-Callejo, David, Romero, Atocha, Sánchez-Beato, Margarita, Torrente, María   +13 more
core   +3 more sources

Update on Lorlatinib: Role in Reducing the Risk of Disease Progression in ALK-Positive NSCLC

Cancer Management and Research, 2022
Karen M Yun, Lyudmila A Bazhenova Department of Hematology-Oncology, Moores Cancer Center at UC San Diego Health, La Jolla, CA, USACorrespondence: Lyudmila A Bazhenova, Department of Hematology-Oncology, Moores Cancer Center at UC San Diego Health, 3855 ...
Yun KM, Bazhenova LA
doaj  

Acquired G2032R Resistance Mutation in ROS1 to Lorlatinib Therapy Detected with Liquid Biopsy

Current Oncology, 2022
Lorlatinib, a third-generation anaplastic lymphoma kinase (ALK)/receptor tyrosine kinase inhibitor (ROS1), demonstrated efficacy in ROS1 positive (ROS1+) non-small cell lung cancer (NSCLC), although approval is currently limited to the treatment of ALK ...
Balázs Jóri, Markus Falk, Iris Hövel, Peggy Weist, Markus Tiemann, Lukas C. Heukamp, Frank Griesinger   +6 more
doaj   +1 more source